Gemphire Therapeutics Inc. (GEMP) EPS Estimated At $-0.72

March 20, 2018 - By wolcottdaily

 Gemphire Therapeutics Inc. (GEMP) EPS Estimated At $ 0.72

Analysts expect Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report $-0.72 EPS on March, 21.They anticipate $0.06 EPS change or 7.69 % from last quarter’s $-0.78 EPS. After having $-0.82 EPS previously, Gemphire Therapeutics Inc.’s analysts see -12.20 % EPS growth. The stock decreased 3.58% or $0.26 during the last trading session, reaching $7.01. About 236,772 shares traded or 90.81% up from the average. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has 0.00% since March 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Ratings Coverage

Among 3 analysts covering Gemphire Therapeutics (NASDAQ:GEMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Gemphire Therapeutics has $25 highest and $15 lowest target. $19’s average target is 171.04% above currents $7.01 stock price. Gemphire Therapeutics had 3 analyst reports since August 30, 2016 according to SRatingsIntel. The stock of Gemphire Therapeutics Inc. (NASDAQ:GEMP) earned “Buy” rating by Jefferies on Tuesday, August 30. Canaccord Genuity initiated it with “Buy” rating and $17 target in Tuesday, August 30 report. RBC Capital Markets initiated the stock with “Outperform” rating in Tuesday, August 30 report.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $96.57 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.